MetaVia Inc. — Director's Dealing 2017

May 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2017-05-30

Reporting Person: Gullans Steven R. Ph.D. (Director, Interim President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-30	Employee Stock Option (right to buy)	$10.26	A	60000	Acquired	2027-05-29	Common Stock (60000)	Direct

Footnotes

F1: The option vests in 12 equal consecutive monthly increments, so that all of the shares will be vested on the one year anniversary of the date of grant, subject to acceleration upon the appointment of a permanent President and Chief Executive Officer.